GS-US-548-5916: Magrolimab Combinations in Recurrent or Metastatic HNSCC
Condition: Head and Neck Squamous Cell Carcinoma
Sponsor: Gilead Sciences, Inc.
Protocol GS-US-548-5916: A Phase 2 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
Patients will be randomized 1:1 to receive treatment with one of two treatment arms:
- Arm A: Magrolimab + Pembrolizumab + 5-FU + Platinum chemotherapy
- Arm B: Pembrolizumab + 5-FU + Platinum chemotherapy
Eligible patients will have a recurrent or metastatic head and neck squamous cell carcinoma that has not yet been treated in the recurrent/metastatic setting.
Eligible primary tumor sites include: oropharynx, oral cavity, hypopharynx, and larynx.
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.